[Skip to Content]
[Skip to Content Landing]
September 19, 1942


JAMA. 1942;120(3):206-207. doi:10.1001/jama.1942.02830380038013

The intradermal test for toxicity of plasma suggested by Levine and State1 of the University of Minnesota may prove to be a valuable diagnostic aid in clinical medicine and serve as a guide to the preparation of nontoxic commercial products. Contrary to some published views2 and to the printed instructions on many lyophilized commercial plasmas, the intravenous administration of human plasma is not "entirely innocuous." Polayes and Squillace,3 for example, recently reported a "near fatal" anaphylactic shock on transfusion of 1 patient with lyophilized plasma, a reaction from which the patient recovered only after heroic anti-shock therapy. Subsequent tests revealed an in vitro incompatibility between the lyophilized plasma and the patient's own blood, a prompt agglutination of the patient's erythrocytes taking place, which Polayes assumed to be due to isoagglutinins in the commercial plasma. As a routine precautionary measure he suggested a pretransfusion matching of plasma and

First Page Preview View Large
First page PDF preview
First page PDF preview